(Q67577062)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

15 September 2019

title

Therapy for chronic hepatitis B with lymphoblastoid interferon-alpha and levamisole (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

15 September 2019

1 reference

1 reference

1 reference

5

P. Pontisso

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1427652

25 September 2022

author name string

G. Fattovich

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1427652

25 September 2022

G. Giustina

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1427652

25 September 2022

L. Brollo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1427652

25 September 2022

M. Guido

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1427652

25 September 2022

F. Noventa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1427652

25 September 2022

A. Alberti

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1427652

25 September 2022

language of work or name

English

0 references

publication date

1 November 1992

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

15 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

15 September 2019

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

15 September 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

15 September 2019

page(s)

1115-1119

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

Natural history and prognostic factors for chronic hepatitis type B

15 September 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

The general immunopharmacology of levamisole

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Levamisole therapy in chronic type B hepatitis. Results of a double-blind randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Changes in serum hepatitis B virus (HBV) DNA positivity in chronic HBV infection: results of a long-term follow-up study of 138 patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon alfa-2a by intramuscular injection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Adenine arabinoside monophosphate (vidarabine phosphate) in combination with human leukocyte interferon in the treatment of chronic hepatitis B. A randomized, double-blinded, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Failure of acyclovir to enhance the antiviral effect of alpha lymphoblastoid interferon on HBe-seroconversion in chronic hepatitis B. A multi-centre randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Therapy of chronic hepatitis B with recombinant human alpha and gamma interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Loss of HBsAg with interferon therapy in chronic hepatitis B virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B

1 reference

https://api.crossref.org/works/10.1002%2FHEP.1840160503

7 January 2021

Identifiers

DOI

10.1002/HEP.1840160503

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:1427652%20AND%20SRC:MED&resulttype=core&format=json

15 September 2019

1 reference